mRNA-1283

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]

mRNA-1283
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Trade namesSpikevax[1]
Routes of
administration
Intramuscular

An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 ºC).

Clinical Trial

In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety. As of May 2022, the trial is in Phase 2 [4]


References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.